预约演示

Sanofi's $1.5B pact with Teva Teva in IBD adds fuel to anti-TL1A race against Merck, Roivant and Pfizer

2023-10-04

交易

并购引进/卖出抗体药物偶联物

A new player has entered the anti-TL1A race, with Sanofi securing a development and commercialization deal with Teva for its monoclonal antibody under investigation for inflammatory bowel disease.

Teva is set to receive €469 million ($500 million) upfront and up to €940 million ($1 billion) in development and launch milestones, the companies revealed early Wednesday morning.

In the anti-TL1A contest, Roivant is already in the mix when it teamed up with Pfizer for RVT-3101, as is Merck, which bought Prometheus Biosciences in a deal worth $10.8 billion for MK-7240.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构